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Abstract
Background: The UL97 protein kinase of human cytomegalovirus phosphorylates the antiviral drug ganciclovir and
is the target of maribavir action. A detailed enzyme kinetic analysis of maribavir on the various enzymatic functions
of wild type and ganciclovir resistant forms of UL97 is required.
Methods: Wild type and site directed mutant forms of the human cytomegalovirus UL97 gene product were
expressed using recombinant baculoviruses and the purified products used to assess the effects of maribavir on
the ganciclovir (GCV) kinase and protein kinase (PK) activities.
Results: Maribavir was a potent inhibitor of the autophosporylation of the wild type and all the major GCV
resistant UL97 mutants analysed (M460I, H520Q, A594V and L595F) with a mean IC50 of 35 nM. The M460I
mutation resulted in hypersensitivity to maribavir with an IC50 of 4.8 nM. A maribavir resistant mutant of UL97
(L397R) was functionally compromised as both a GCV kinase and a protein kinase (~ 10% of wild type levels).
Enzyme kinetic experiments demonstrated that maribavir was a competitive inhibitor of ATP with a Ki of 10 nM.
Discussion: Maribavir is a potent competitive inhibitor of the UL97 protein kinase function and shows increased
activity against the M460I GCV-resistant mutant which may impact on the management of GCV drug resistance in
patients.
Background
The UL97 gene of human cytomegalovirus encodes a 690
amino acid nuclear serine/threonine protein kinase that
is present in the virion and is critical for efficient viral
replication [1-8]. The precise function of UL97 in the
replication cycle has not been fully elucidated but UL97
has been implicated in replication, viral DNA packaging,
nuclear egress, virion morphogenesis and cell cycle
manipulation [9-15]. The full range of targets for UL97
kinase action are also undefined although the viral UL44
protein is one viral substrate [16] and pUL97 complexes
with the tegument phosphoprotein pp65 (ppUL83) [17].
UL97 also phosphorylates the antiviral nucleosides ganci-
clovir (GCV) and acyclovir [18-21], the former being the
major drug currently used to control HCMV replication
in vivo [22,23]. In the era preceding the deployment of
highly active antiretroviral therapy for HIV infection,
long term GCV therapy for cytomegalovirus retinitis led
to the development of GCV resistance in up to 40% of
patients [24] although the frequency appears to be lower
in transplant recipients receiving GCV prophylaxis
[24-27]. A number of studies have investigated the mole-
cular basis for resistance of HCMV to GCV and show
that a small number of mutations in UL97 (at amino
acids M460, H520, A594 and L595) account for the
majority (~85%) of clinically significant drug resistance
[28-31]. Subsequent to the development of UL97 muta-
tions, resistance at the DNA polymerase locus can also
occur [32-34]. In vivo dynamic modelling has shown that
these mutant viruses are less fit than their wild type
counterparts and, in the absence of selective drug pres-
sure, wild type virus is between 5-10% more fit than the
GCV resistant mutants [35].
The benzimidazole class of compounds are novel inhi-
bitors of HCMV replication. The progenitor, BDCRB (2-
bromo-5,6-dichloro-1-(b-D-ribofuranosyl benzimidazole)
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and the UL56 terminase proteins [36] whereas the related
compound maribavir (5,6-dichloro-2-(isopropylamino)-1-
beta-L-ribofuranosyl-1H-benzimidazole; also known as
1263W94 and benzamidavir) targets the protein kinase
activity of UL97 (37). Maribavir has potent antiviral activ-
ity against HCMV [37] and EBV [38], with an IC50
approximately 4-to 10-fold lower than that observed for
GCV against HCMV replication in vitro and is active
against HCMV strains resistant to ganciclovir, foscarnet
and cidofovir [39]. Cell culture of HCMV in the presence
of maribavir routinely leads to drug resistance involving a
single amino acid change in UL97: L397R [37]. However,
recently, using a clinical isolate with a mutation in the
exonuclease domain of the viral DNA polymerase addi-
tional UL97 mutations at amino acids 411 (H to L/Y/N),
409 (T to M) and 353 (V to A) have also been described
[40,41]. These mutations cluster more closely to the pro-
posed ATP binding domain of UL97. Maribavir has
undergone phase I and II clinical trials and phase III pro-
phylaxis trials in solid organ and stem cell transplant
recipients [42-44]. Mutations which contribute to drug
resistance against maribavir have also been identified in
UL27 although the precise function of this protein in the
viral life cycle remains to be fully defined [45].
At present, a detailed enzyme kinetic analysis of drug
resistant UL97 mutants has not been undertaken. In the
present study, we have used recombinant baculovirus
systems to produce UL97 protein of high purity to per-
form a detailed biochemical analysis of the kinetics of
autophosphorylation of a series of the clinically relevant
UL97 GCV resistant mutants and a selection mutations
in conserved protein kinase domains in UL97 to deter-
mine the effects of maribavir on the autophosphoryla-
tion capacity of these mutants. The data provide insight
into the mechanism of action of maribavir and highlight
the impact that certain GCV resistant mutations have
on the inhibitory profile of maribavir.
Methods
Cells and viruses
Spodoptera frugiperda 21 (Sf21) cells (Invitrogen) were
maintained in TC100 medium (Life Technologies, Pais-
ley Scotland) supplemented with 10% fetal bovine
serum, 50 IU of penicillin per ml, and 50 μg of strepto-
mycin per ml. Wild-type linearized Autographa califor-
nica multiple nuclear polyhedrosis virus (AcMNPV;
Invitrogen, Scotland) was used to construct the recom-
binant baculoviruses. The Towne strain of cytomegalo-
virus was propagated in primary human embryonic lung
fibroblasts maintained in DMEM medium (Life Tech-
nologies, Scotland) supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 100 IU of penicillin per ml,
and 100 μg of streptomycin per ml in 5% CO2.
Cloning of the HCMV UL97 ORF
Human embryonic lung fibroblasts were infected with
the Towne strain of HCMV at a multiplicity of infection
(m.o.i.) of 5 and 72 h later DNA extracted using the
Wizard genomic purification kit (Promega, Southamp-
ton UK). The extracted DNA (1 ug) was used as the
template for a PCR reaction to generate the full length
UL97. The primers (5’-GGG GTA CCC ATG TCC TCC
GCA CTT CGG TCT CGG and 5’-CCC AAG CTT
TTA CTC GGG GAA CAG TTG GCG GCA) were
designed to generate an amplicon with a 5’ K p nIa n da
3’ Hind III restriction site. PCR conditions consisted of
95°C for 5 min followed by cycling at 60°C for 3 min,
72°C for 10 minutes and 95°C for 3 minutes using the
Bioline (UK) high fidelity Taq polymerase mixture (Bio-
X-Act) according to the manufacturer’s instructions.
The 2160 bp DNA amplicon was purified using the
Wizard™PCR prep DNA purification system (Promega,
UK) and ligated into the pGEM-T Easy vectors (Pro-
mega, UK) for subsequent sequencing of the entire
UL97 ORF. The pGEM-UL97 construct was restricted
with Kpn I and Hind III, the UL97 fragment purified
and ligated into the pMelBac C or pBluBacHis C trans-
fer vectors (Invitrogen, Scotland), which had been simi-
larly restricted enabling directional cloning of the UL97
in the correct open reading frame. The pMelBac transfer
vector allowed the incorporation of a N-terminal honey
bee melittin secretion signal onto the UL97 protein
while the pBluBacHis incorporated an N-terminal hexa-
histidine tag.
Site directed mutagenesis of the UL97 ORF
Point mutations were introduced into the pMelUL97
transfer vectors using the GeneEditor™in vitro Site
Directed Mutagenesis system (Promega, Southampton,
UK). Briefly, 100 ng of denatured template DNA was
added to an annealing solution of 0.25 pmol of the
appropriate phosphorylated selection oligonucleotide
(top strand), 1.25 pmol of phosphorylated mutagenic oli-
gonucleotide and 10 × TM buffer (100 mM Tris, 100
mM MgCl2). Annealing was performed for 15 min at
37°C and mutant strand synthesis and ligation per-
formed at 37°C for 90 min following addition of 10 ×
synthesis buffer (100 mM Tris-HCl, pH7.5, 5 mM
d N T P ,1 0m MA T P ,2 0m MD T T ) ,T 4D N Ap o l y m e r -
ase, and T4 DNA ligase according to manufacturers
instructions. Following the mutagenesis reaction, 1.5 μl
of each reaction was transformed into BMH 71-18 mutS
E.coli , the plasmid harvested and transformed into
JM109 E.coli in an appropriate antibiotic selection mix
to ensure good segregation of the mutant and wild type
plasmids. The mutant UL97 ORFs were DNA sequenced
to confirm the specific introduction of the mutation and
the absence of other mutations and recombinant
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used to introduce the desired mutations were as follows:
K355Q (5’-CGC GTG GTC GAG GTG GCG CG);
L397R (5’-CGC GGT CTG CGC ACG GCC AC);
D456A (5’-TGC CAC TTT GCC ATT ACA CCC);
M460I (5’-C ATT ACA CCC ATT AAC GTG C);
N461G (5’-ACA CCC ATG AAA GTG CTC ATC);
H520Q (5’-GAA TGT TAC CAG CCT GCT TTC C);
A594T (5’-C TGC CGC ACG TTG GAG AAC GG);
L595F (5’-C TGC CGC GCG TTT GAG AAC GG);
H662L(5’-ACC ATG CTG CTC GAA TAC GTC) and
V665I (5’-CAC GAA TAC ATC AGA AAG AAC G).
Production of recombinant baculoviruses expressing wild
type and mutant forms of UL97
Recombinant baculoviruses were constructed by co-
transfection of the transfer vectors with linear, wild type
AcMNPV DNA into Sf21 cells using InsectinPlus™lipo-
somes (Invitrogen, Scotland). Recombinant baculo-
viruses BVBMUL97 or BVBBHUL97 were then
harvested 72 hours post transfection and expanded by
two rounds of plaque purification to high titre stocks.
Insertion of the UL97 and absence of the wild type
AcMNPV were confirmed by PCR using primers either
side of the cloning sites. Expression of the wild type or
mutant UL97 proteins was assessed using SDS-PAGE
and Western blotting following infection of Sf21 insect
cells at an m.o.i. of 10. After 72 h, cells were lysed and
proteins were separated by SDS-PAGE and electrophor-
etically transferred onto a polyvinylidene difluoride
(PVDF; Bio-Rad) membrane by using a semi-dry blotter
(Pharmacia Biotech, Buckinghamshire, UK). The mem-
brane was incubated for 1 h at room temperature in
blocking buffer (3% bovine serum albumin (Sigma Che-
micals, Dorset, UK) in TBS [10 mM Tris-HCl, pH 7.5,
150 mM NaCl]), then washed with 0.05% Tween 20-
0.1% Triton X-100 in TBS. The membrane was incu-
bated with a 1/500 dilution of mouse UL97-specific
polyclonal antisera (a gift from Dr D Michel, Universi-
tatsklinikum Ulm, Abteilung Virologie, Ulm, Germany)
in blocking buffer for 1 h at room temperature then
incubated with 1:6,000 dilution of alkaline phosphatase-
conjugated goat anti-mouse IgG (Bio-Rad, Hemel
Hempstead, UK) for 1 h at room temperature. The
membrane was further washed, and immunoreactive
bands were visualized by incubation of the membrane in
a staining solution consisting of one tablet of 5-bromo-
4-chloro-3-indolylphosphate-nitroblue tetrazolium chlor-
ide (Sigma Chemicals, Dorset, UK) dissolved in 10 ml of
distilled H2O.
Purification of the wild type and mutant UL97 proteins
Sf21 insect cells were infected with wild type or mutant
UL97 recombinant baculoviruses at an m.o.i. of 10,
incubated at 28°C and harvested 72 hours post infection.
Cells were sonicated three times in ice cold sonication
buffer (50 mM Tris-HCl, pH 7.6, 100 mM NaCl, 0.1%
Nonidet P-40, 10% glycerol, 10 μg/ml Aprotinin and
Leupeptin and 1 mM Pefabloc), for 10 seconds at
5 microns. Disrupted cells were centrifuged for 10 min-
utes at 4°C at 13000 × g. Ammonium sulphate was
added to the sonicated crude lysate to give a% saturation
of 20%-40%, at which the maximum concentration of
UL97 was precipitated. The protein precipitate was cen-
trifuged at 3000 × g for 40 minutes at 4°C, resuspended
in 20 mM Tris-HCl, pH 8.5, 100 mM NaCl, 0.5% Sarko-
syl and dialysed overnight to give a total of 1/10 000
dilution of the ammonium sulphate. The insoluble pro-
teins were removed by centrifugation and the UL97 dia-
lysed into 20 mM Tris-HCl, pH 8.0, 20 mM NaCl
overnight to perform anion exchange chromatography.
The soluble protein fraction was applied to a DEAE
sepharose column at 4°C for 1 hour and the bound
protein eluted from the sepharose by buffer containing
0.5 M NaCl. The eluted proteins were concentrated
using a Centricon-50 concentration tube. Finally, the
UL97 was subjected to immuno-affinity purification.
Phosphorylation of Ganciclovir (GCV) by UL97
Sf21 insect cells were infected with wild type or mutant
UL97 recombinant baculoviruses at an m.o.i. of 10.
After 48 h incubation at 28°C, the culture medium was
replaced with fresh medium containing 1.0 mM GCV
and [
3H] GCV (0.55 Mbq, Moravek Radiochemicals,
California, USA) After a further 24 hours of incubation,
nucleotides were harvested by acid hydrolysis (0.5 M
perchloric acid), neutralisation to pH 7.5 (2.5 M KOH,
1.5 M KH2PO4) and centrifugation (13000 × g). 50 μl
aliquots of supernatant were spotted onto 20 mm dia-
meter DEAE-coated DE81 chromatographic paper discs
and the monophosphorylated GCV allowed to bind. The
discs were washed twice in 3 ml 10 mM ammonium
acetate for 10 minutes and twice in 95% ethanol for
10 minutes. After drying 5 ml of sigmafluor was added
(Sigma Chemicals, Dorset, UK) and the radioactivity
determined by liquid scintillation counting.
Autophosphorylation of UL97
Analysis of the autophosphorylation of wild type and
mutant UL97 protein species was performed by a stan-
dard protein kinase assay as previously described (46).
Briefly, purified protein was added to 2× protein kinase
buffer (100 mM Tris HCl, pH9.0, 20 mM MgCl2,1 0μM
ATP, 4 mM DTT, 2 M NaCl) and 370 KBq [g
32P] ATP
(Amersham), made up to 20 μlw i t hS D Wa n di n c u -
bated at 37°C. The reactions were terminated by the
addition of 2× SDS sample buffer followed by boiling
for 3 minutes. The amount of radiolabelled phosphate
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SDS-PAGE and measured using the Biorad Mulitanalyst.
The protein kinase assays were initially performed for 2
to 60 minutes to determine the maximum rate of phos-
phate incorporation, all assays were then performed at
the maximum rate which equated to 5 minutes.
Enzyme kinetic analysis
Enzyme kinetic analysis was performed on the purified
wild type and mutant UL97 protein species as above using
increasing concentrations of ATP (2 μMt o2 0μM). The
amount of incorporated radiolabelled phosphate was
plotted against the concentration of ATP in a Lineweaver
Burke plot to determine the Km for ATP for each UL97
species. The effect of maribavir upon the rate of radiola-
belled phosphate incorporation by wild type or mutant
UL97 was determined by protein kinase assays at a fixed
concentration of maribavir (0.5 μM) as above, or with
increasing concentrations of maribavir (0.01 μMt o5 . 0
μM) to determine the IC50 of maribavir for each UL97
species. In order to determine the nature of the inhibition
mediated by maribavir, plots of 1/v vs 1/ATP with increas-
ing concentrations of maribavir were constructed. Compe-
titive inhibition was evident if the family of lines
cconverged on the y-axis at 1/Vmax. The change in slope
caused by the addition of maribavir was used to calculate
the Ki using standard enzyme kinetic equations viz.
Km Km
I
Ki
II +− =+ []
[]
⎛
⎝
⎜ ⎜
⎞
⎠
⎟ ⎟ 1
where Km
+I is the apparent Km in the presence of
the inhibitor, Km
-I is the Km in the absence of the inhi-
bitor, Ki is the dissociation constant of the inhibitor and
[I] the concentration of the inhibitor.
Results
Expression and purification of UL97
Expression of large amounts of wild type and mutant
forms of UL97 for the subsequent biochemical analyses
was achieved by using two different recombinant bacu-
lovirus expression system using either a C-terminal His
tag or fusion of the N-terminus with the honey-bee mel-
litin signal sequence. All mutant constructs were DNA
sequenced to ensure that only the desired mutation had
been introduced. Expression levels of UL97 were sub-
stantially higher in the honey-bee melittin system rather
than the his-tag system and so the former system was
used for the subsequent studies (Figure 1). Wild type or
mutant UL97 proteins were purified using a combina-
tion of ammonium sulphate precipitation followed by
anion exchange and affinity chromatography. The var-
ious UL97 proteins were purified to > 90% homogeneity,
were expressed at similar levels and were used at the
Figure 1 Coomassie Blue stained SDS-PAGE gel showing the time course of expression of the wild type UL97 protein using either the
honey-bee mellitin (BVBM-UL97; lanes 1-3) or the BlueBacHis (BVBBH-UL97; lanes 4-6) recombinant baculovirus system illustrating the
higher expression levels observed in the honey-bee mellitin system. For comparison, a recombinant baculovirus expressing the LacZ gene
(BV-LacZ; lanes 7-10) and mock infected insect cells (mock; lanes 10-12) are also shown. Arrows indicate the UL97 and LacZ proteins and
molecular weight markers.
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(Figure 2A and 2B).
GCV phosphorylation by mutant UL97 proteins
Insect cells were infected with the wild type or mutant
UL97-expressing baculoviruses at high multiplicity and
after 48 hours, the medium was supplemented with tri-
tiated GCV. The phosphorylation of GCV catalysed by
each of the mutant UL97 proteins was compared to wild
type GCV phosphorylation (normalised to 100%). The
data summarised in Figure 3 show that GCV phosphory-
lation by the genotypic GCV-resistant UL97 mutants
(M460I, H520Q, A594T and L595F) was reduced to
between 10% and 20% of the levels of GCV phosphoryla-
tion catalysed by the wild type UL97 protein. As
expected, mutation at the invariant lysine (K355Q) pro-
duced a protein that was unable to phosphorylate GCV.
Although mutation of M460 showed a substantial loss of
GCV phosphorylation, mutation of the nearby 456 codon
had no effect on GCV phosphorylation. Mutations
around the His-X-aromatic-hydrophobic motif at codons
H662L and V665I showed a reduction in GCV phosphor-
ylation by 12% and 72% of wild type levels respectively.
Interestingly, the maribavir-resistant UL97 mutant
(L397R) exhibited a significant impairment in GCV phos-
phorylation (approximately 10% of wild type).
Kinetic analysis of UL97 autophosphorylation
Enzyme kinetic analyses were performed on the wild type
and mutant UL97 proteins to calculate the Km for ATP.
The purified UL97 proteins were incubated in a protein
kinase assay for 5 minutes in constant reaction condi-
tions, but with increasing ATP concentrations (2 μMt o
20 μM). The amount of phosphate incorporated was
Figure 2 A) SDS-PAGE analysis of purified wild type and a selection of mutant UL97 proteins used in the study. B) Western blot analysis
showing the comparable expression levels of wild type and mutant UL97 proteins.
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Lineweaver Burke plots used to calculate the Km for
ATP. In the case of the wild type UL97, the Km for ATP
was 27 ± 2.2 μM and for the GCV resistant mutants, the
Km values were as follows: M460I, 28 ± 2 μM; H520Q.
25 ± 2.4 μM; A594T, 40 ± 4.2 μM; L595F, 31 ± 4.5 μM.
An alternative analysis which gives the relative efficiency
of usage of ATP was performed where Vmax/Km was
calculated. These data showed that the GCV resistant
mutant proteins were of similar efficiency as the wild
type at utilising ATP than the wild type protein except
for the M460I mutant which was substantially less effi-
cient (Vmax/Km for wild type = 7.2 s
-1; M460I = 4.5 s
-1;
H520Q = 8.4 s
-1; A594T = 5.5 s
-1; L595F = 6.4 s
-1).
Effects of maribavir on the autophosphorylation of wild
type and mutant UL97 species
In the absence of maribavir, the GCV resistant UL97
mutants H520Q, A594T and L595F exhibited autopho-
sphorylation levels equivalent to the wild type UL97
(Figure 5). However, the M460I mutant consistently
exhibited approximately 85% of the autophosphorylation
levels of the wild type UL97 (p = 0.01). Mutations of the
invariant lysine (K355Q) completely negated autopho-
sphorylation, as did mutation of the arginine at amino
acid 461. Interestingly, the mutation that confers mari-
bavir resistance to UL97 (L397R) resulted in a reduction
in autophosphorylation to approximately 8% of the wild
type levels. The remaining mutations within the UL97
gene (D456A, H662L and V665I) did not result in any
change in autophosphorylation compared to that cata-
lysed by the wild type UL97.
In the presence of a fixed concentration of maribavir
(0.5 μM) the autophosphorylation of every form of
UL97 investigated (mutant and wild type) was reduced
to below 10% of the total phosphorylation of the wild
type UL97 protein (Table 1). As expected, the autopho-
sphorylation of the L397R mutant, which is resistant to
maribavir, was unaffected although the absolute autop-
hosphorylation level of this mutant is already substan-
tially reduced (see above).
Quantitative image analysis of the autoradiographs
generated from the protein kinase assays using increas-
ing concentrations of maribavir allowed calculation of
the IC50 for each UL97 protein under investigation (Fig-
ure 6). The IC50 for wild type UL97 was 34 nM, and for
the mutants H520Q, A594T, L595F, the D456A, H662L
and V665I the IC50 was 33 nM, 31 nM, 28 nM 34 nM,
40 nM and 30 nM respectively. There was no autopho-
sphorylation of the K355Q and N461G mutants hence
Figure 3 Ganciclovir (GCV) phosphorylation catalysed by the wild type and UL97 mutant proteins (designated by the amino acid
change present). Insect cells were infected with the wild type or mutant UL97 expressing baculoviruses at an MOI 10. The medium was
supplemented with tritiated GCV at 48 hours. The nucleotides were harvested at 72 hours and bound to DE81 filter paper. The phosphorylated
GCV is plotted as percentage phosphorylation compared to the wild type UL97 (set at 100%). Data are the mean +/- one standard deviation of
three experiments.
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maribavir. The maribavir-resistant mutant (L397R) did
not exhibit a reduction in autophosphorylation even
when drug concentrations were increased to 100 μM. In
contrast to the comparable IC50 values observed
between wild type UL97 and the GCV resistant mutants
at amino acids 520, 594 and 595, the M460I mutant
was hypersensitive to maribavir with an IC50 of 4.8 nM
(Figure 6).
Mechanism of action of maribavir
In order to determine whether maribavir was acting as a
competitive inhibitor of ATP, a protein kinase assay was
performed using the wild type UL97 protein with
increasing concentrations of ATP (2 μMt o2 0μM) in
the presence of different concentrations of maribavir.
The level of UL97 autophosphorylation decreased upon
addition of maribavir at each ATP concentration and
for each increase in maribavir concentration (Figure 7).
Figure 4 The kinetics of autophosphorylation of UL97 (panel A). The density of the bands was analysed by the BioRad Multianalyst software
and then plotted against the corresponding ATP concentration (B). Data shown are for the wild type UL97. Data are the mean +/- one standard
deviation of three experiments.
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plot shown in Figure 7 crossed the y-axis at 1/Vmax
and was consistent with maribavir acting as a competi-
tive inhibitor of ATP. The computed Ki for maribavir
was 10 ± 0.8 nM.
Discussion
UL97 is an enigmatic protein which likely possesses a
number of roles in the viral life cycle relating to both
viral and cellular processes [4-10]. The protein autopho-
sphorylates a number of serine and threonine residues
although there is no evidence that it is a substrate for
cellular serine/threonine kinses. The availability of a
new class of antiviral compounds based upon a benzimi-
dazole core structure that target the kinase activity of
UL97 coupled with purified UL97 allowed us to under-
take a detailed quantitative biochemical analysis of the
functional implications of a spectrum of mutations,
including the key mutations giving rise to clinically sig-
nificant drug resistance against either GCV or maribavir,
on both the GCV and protein kinase functions of UL97.
Initially we investigated the function of the mutant
UL97 proteins as GCV kinases. Consistent with other
studies [46] the results showed that the GCV kinase
Figure 5 Effects of maribavir on the autophosphorylation of wild type UL97 and the various mutant proteins. Autoradiographs showing
the Inhibition of autophosphorylation of wild type and mutant UL97 proteins by maribavir. The presence or absence of maribavir (0.5 μM) is
indicated by + or-above each lane. UI = uninfected control insect cells.
Shannon-Lowe and Emery Herpesviridae 2010, 1:4
http://www.herpesviridae.org/content/1/1/4
Page 8 of 13efficiency of the well characterised GCV resistant
mutants of UL97 (M460I, H520Q and A594V and
L595F) was between 10-15% of the wild type levels.
Mutations in other key domains of UL97 showed a vari-
ety of GCV kinase activities. The D456A mutant showed
similar GCV phosphorylation levels as the wild type
protein despite being part of the highly conserved kinase
domain whereas the H662L mutant phosphorylated
GCV to 82% of wild type levels. In contrast, the N461G
mutant and mutation of the invariant protein kinase
lysine at amino acid 355 led to the complete loss of
G C Vk i n a s ea c t i v i t yw h i l et h eV 6 6 5 Im u t a n tr e d u c e d
GCV phosphorylation to 25% of wild type levels. Inter-
estingly, the maribavir resistant mutant L397R was
severely debilitated as a GCV kinase (~8% of wild type
levels) implying that this mutant would also be cross-
resistant to GCV. These data are consistent with recent
in vitro studies of this mutant [47].
We next investigated the autophosphorylation of the
UL97 proteins. The Km for ATP was similar for both
wild type and mutant UL97 proteins (27 μM) and was
comparable to that observed in previous studies on U69
protein of HHV-6 [48]. However, when the Vmax/Km
were compared most of the GCV resistant UL97 pro-
teins appeared to be similar to the wild type in their uti-
lisation of ATP with the exception of the M460I
mutation which was less efficient. This observation is
consistent with the observation that the autophosphory-
lation levels observed for the M460I were reduced com-
pared to wild type and other GCV resistant mutants
analysed in this study.
Previous data using UL97 mutants of the invariant
lysine at codon 355 and the conserved asparagine at
codon 461 has shown that UL97 autophosphorylation is
a prerequisite for the phosphorylation of GCV [15]. We
have extended these analyses to include a substantial
range of additional mutants and investigated the effects
of maribavir on each mutant species. Interestingly, with
the exception of mutations at essential amino acids
(L355 and N461) the majority of GCV resistant mutants
showed autophosphorylation levels comparable to the
wild type. The only exceptions were the M460I muta-
tion which exhibited autophosphorylation at 83% of
wild type levels and the maribavir resistant mutant
(L397R) where autophosphorylation was reduced to
~10% of wild type levels. Thus, certain UL97 mutations
can possess both high level protein and GCV kinase
activity ((H662L, D456A) or high level protein kinase
function and low level GCV kinase activity (M460I,
A594T, L595F, H520Q). However, only the L397R
mutation exhibited both low protein and low GCV
kinase activity. Addition of maribavir resulted in a sub-
stantial reduction in the autophosphorylation of wild
type and all mutant UL97 proteins except for mutations
that either negated protein kinase function (K355Q) or
contained the maribavir resistance mutation (L397R).
Based upon data for GCV resistant UL97 mutants in
vivo [35], the low level of autophosphorylation asso-
ciated with the L397 mutant would result in this
mutant being substantially less fit than wild type virus
in vivo. It will be interesting to perform similar autop-
hosphorylation analysis on the recently described addi-
tional maribavir resistant mutants [42,43] and extend
these studies to determine relative fitness differences
between these maribavir resistant viruses and their wild
type counterparts.
The IC50 for maribavir of all the UL97 species were
v e r ys i m i l a rw i t ham e a nv a l u eo f3 3n M( + / -1 2n M ) .
Importantly, each of the phenotypic GCV-resistant
mutants exhibited the equivalent sensitivity to maribavir
as the wild type UL97. However, the IC50 of maribavir
for the M460I mutant (4.8 nM) showed that this mutant
was approximately four times more sensitive to the
drug. This observation may reflect the position of the
460 codon in the conserved protein kinase consensus
sequence HRDLKXXN (amino acids 454-461 in UL97)
that comprises the catalytic loop. Unfortunately, the
N461G mutation exhibited a total loss in autophosphor-
ylation and so further investigations were precluded.
The fact that the L397R mutation (and the other more
recently described mutations [42]) reside in the protein
kinase subdomain III, which is involved in the stabilisa-
tion of the interaction between the invariant lysine and
the a-a n db- phosphates of the ATP, suggests that
maribavir may interfere with this interaction. We
showed that the inhibition by maribavir was alleviated at
high concentrations of ATP and increasing concentra-
tions of maribavir reduced the incorporation of radiola-
belled phosphate in the UL97 autophosphorylation
Table 1 Effects of maribavir on the relative levels of
autophosphorylation of the wild type and mutant UL97
proteins
Ul97 species % autophosphorylation
No Maribavir Plus Maribavir
Wild type 100 4.5 ± 2.0
K355Q 1.0 ± 0.9 0.5 ± 0.8
L397R 7.8 ± 3.3 7.8 ± 4.5
D456A 104.0 ± 4.0 5.0 ± 1.0
M460V 86 ± 2.0 3.9 ± 2.0
N461G 8.0 ± 1.8 4.2 ± 2.0
H520Q 103.5 ± 3.5 3.8 ± 1.5
A594T 107.0 ± 5.0 2.5 ± 2.5
L595F 100.0 ± 8.0 5.0 ± 1.0
H662L 102.5 ± 4.5 3.0 ± 1.5
V665I 100.5 ± 2.0 3.0 ± 1.5
The data are normalised relative to wild type and show the mean and
standard deviation of triplicate analysis.
Shannon-Lowe and Emery Herpesviridae 2010, 1:4
http://www.herpesviridae.org/content/1/1/4
Page 9 of 13Figure 6 IC50 of maribavir for the wild type and mutant UL97 Proteins. The wild type and mutant UL97 proteins were subjected to protein
kinase assays with varying concentrations of maribavir (0.01-1.0 μM). The autoradiographs were analysed using the BioRad Multianalyst software
and UL97 phosphorylation plotted as a percentage of the total phosphorylation in the absence of maribavir. An exponential decay curve was
fitted and the IC50 of maribavir was determined for each of the proteins. The alteration of x-axis scale of the M460I graph should be noted. The
IC50 for each species is shown.
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Page 10 of 13assay. When the Lineweaver-Burke plots were con-
structed, the resulting family of lines converged on the
Y-axis at approximately 1/Vmax. These observations
were consistent with maribavir acting as a competitive
inhibitor of ATP with a computed Ki of 10 nM.
In conclusion, we have shown that GCV resistant
mutations in the UL97 kinase do not affect the Km of the
enzyme for ATP but that the UL97 M460 mutation con-
fers hypersensitivity to maribavir. Maribavir is a potent
competetitive inhibitor of ATP and a mutation at L397
that yields maribavir resistance substantially reduces both
the GCV kinase and protein kinase activity of UL97
meaning that maribavir resistant strains of HCMV will
have to be treated with foscarnet or cidofovir.
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